Cerenome Announces Interim Clinical Data for REYOBIQ in Patients with Leptomeningeal Metastases
CNSY Cerenome Inc
$0.63 -11.82%
View chart & analysis → - 1Cerenome, Inc. announced interim clinical data for REYOBIQ involving 10 patients with leptomeningeal metastases through the ReSPECT-LM study.
- 2Analysis showed nausea occurred in 60% of patients, headaches in 40%, and decreases in lymphocyte and white blood cell counts were observed in 40% of participants.
- 3Cerenome aims to initiate a Phase 2 randomized controlled trial for REYOBIQ in 2027.
So what's the key point?
Cerenome shared interim test results for a drug targeting patients with leptomeningeal metastases. Side effects such as nausea were identified in 60% of patients.
Source InvestorsHub +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.